{"filing":{"accession_number":"0001193125-26-283033","cik":"0001701108","ticker":"SPRO","company_name":"Spero Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"d86736d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526283033/d86736d8k.htm"},"events":[{"id":14004,"run_id":12453,"accession_number":"0001193125-26-283033","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Spero Therapeutics held its Annual Meeting on June 23, 2026, with stockholders voting on five matters: reelection of Class III directors (Milind Deshpande and Kathleen Tregoning), ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, amendment to increase authorized common shares from 120 million to 240 million, and approval of the 2026 Stock Incentive Plan authorizing up to 12,895,866 shares for compensatory purposes.","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11310,"accession_number":"0001193125-26-283033","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Stock Incentive Plan, which authorizes issuance of up to 12,895,866 shares for compensatory purposes. This is a classic Item 5.02(e) compensatory arrangement disclosure — approval of an equity incentive plan that will govern future grants to officers, directors, and employees. The materiality stems from the substantial share authorization and its impact on dilution and executive compensation structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:09:40.613314+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11311,"accession_number":"0001193125-26-283033","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a routine stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 120 million to 240 million. While the increase in authorized shares could theoretically enable dilutive issuances, the amendment itself is a standard administrative governance action that does not constitute a material event to a reasonable investor absent evidence of imminent dilutive activity or financial distress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:09:40.613314+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11312,"accession_number":"0001193125-26-283033","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from Spero Therapeutics' Annual Meeting held on June 23, 2026. The filing reports voting outcomes on five matters: reelection of Class III directors (Milind Deshpande and Kathleen Tregoning), ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, amendment to increase authorized shares from 120 million to 240 million, and approval of the 2026 Stock Incentive Plan. These results are material to investors as they reflect governance decisions and capital authorization changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:09:40.613314+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11310,"accession_number":"0001193125-26-283033","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Stock Incentive Plan, which authorizes issuance of up to 12,895,866 shares for compensatory purposes. This is a classic Item 5.02(e) compensatory arrangement disclosure — approval of an equity incentive plan that will govern future grants to officers, directors, and employees. The materiality stems from the substantial share authorization and its impact on dilution and executive compensation structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:09:40.613314+00:00","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-06-25"},{"id":11311,"accession_number":"0001193125-26-283033","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a routine stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 120 million to 240 million. While the increase in authorized shares could theoretically enable dilutive issuances, the amendment itself is a standard administrative governance action that does not constitute a material event to a reasonable investor absent evidence of imminent dilutive activity or financial distress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:09:40.613314+00:00","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-06-25"},{"id":11312,"accession_number":"0001193125-26-283033","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from Spero Therapeutics' Annual Meeting held on June 23, 2026. The filing reports voting outcomes on five matters: reelection of Class III directors (Milind Deshpande and Kathleen Tregoning), ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, amendment to increase authorized shares from 120 million to 240 million, and approval of the 2026 Stock Incentive Plan. These results are material to investors as they reflect governance decisions and capital authorization changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:09:40.613314+00:00","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-06-25"}]}